Skip to content

Group Psychotherapy in Narcolepsy Type 1

Effectiveness of Group Psychotherapy in Patients With Narcolepsy Type 1

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05314556
Enrollment
10
Registered
2022-04-06
Start date
2021-08-01
Completion date
2022-12-31
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Narcolepsy Type 1

Keywords

Narcolepsy Type 1, Narcolepsy, Narcolepsy with cataplexy, Group psychotherapy, Group therapy, Psychotherapy

Brief summary

The aim of this pilot study is to test the benefit of behavior therapy-oriented, method-integrated psychotherapy in an outpatient group setting in patients with narcolepsy type 1. Therefore we collect and evaluate initial data on its effectiveness on the disease in terms of specific symptomatology, emotion regulation, health-related quality of life, and disease processing/acceptance.

Interventions

Additional group psychotherapy for patients with narcolepsy type 1 with standard medication

Sponsors

Cantonal Hospital of St. Gallen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed narcolepsy type 1 according to AASM, examined by an experienced sleep physician including history, clinical examination, polysomnographic examination (PSG) with a multiple sleep latency test (MSLT), possibly also including determination of HLA DQB1 \* 062 and orexin A / hypocretin 1 * Age between 18 and 65 years * Signed informed consent * Exclusion of other clinically relevant organic sleep disorders by means of polysomnography (AHI\>10/h)

Exclusion criteria

* Presence of severe psychiatric comorbidity * Other psychotherapy during the study period * Change of medication used for narcolepsy therapy shortly before the start and during the study period including follow-up measurement. In this case, patients may still complete group therapy, but the data will not be included in the analysis.

Design outcomes

Primary

MeasureTime frameDescription
Fatigue (Severity)Week 0-24German version of the questionnaire Fatigue Severity Scale (FSS; Valko et al., 2008)
Daytime sleepinessWeek 0, Week 6, Week 12, Week 24German version of the questionnaire Epworth Sleepiness Scale (ESS; Johns, 1991)
Sleep qualityWeek 0-24German version of the questionnaire Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 2008)
Emotion regulationWeek 0-24German questionnaire Fragebogen zur Erhebung der Emotionsregulation bei Erwachsenen (FEEL-E; Grob et al., 2014)

Secondary

MeasureTime frameDescription
Anxiety & depressionWeek 0, Week 6, Week 12, Week 24German version of the questionnaire Hospital Anxiety and Depression Scale (HADS; Herrmann et al., 1995; Herrmann-Lingen et al., 2011; Zigmond & Snaith, 1983)
Health-related quality of life (HRQOL)Week 0-24German version of the questionnaire Short Form 12 Health Survey (SF-12; Morfeld et al., 2012)
Disease processing, acceptance & copingWeek 0, Week 6, Week 12, Week 24German questionnaire Freiburger Fragebogen zur Krankheitsverarbeitung (FKV-LIS-SE; Muthny, 1989)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026